Fujifilm Biotechnologies has introduced its groundbreaking ShunzymeX precision purification technology, designed to streamline downstream processing for complex biologics. This innovation will be showcased at the upcoming Festival of Biologics conference in San Diego.
Innovative Collaboration
The ShunzymeX technology is the result of a partnership between Fujifilm Biotechnologies and the University of Edinburgh. This proprietary method utilizes a novel protease, which simplifies the purification process for complex biologics. The integration of an affinity tag allows for the efficient purification of biologic proteins using readily available affinity resins. Following purification, the innovative protease removes the tag without compromising the integrity of the native protein.
Addressing Traditional Challenges
John Stewart, senior vice president of global process development at Fujifilm Biotechnologies, explains that traditional microbial downstream purification faces significant challenges. The variability in size and sequence of microbial-expressed proteins often results in a shortage of suitable affinity resins. This inconsistency can lead to lengthy development cycles, suboptimal yields, and poor purity levels.
Streamlined Development Process
ShunzymeX is poised to transform these traditional methods. By providing a robust affinity chromatography step, this technology has the potential to drastically reduce process development timelines. Stewart emphasizes that the versatility of ShunzymeX allows it to be compatible with various expression systems, making it scalable directly to cGMP standards.
Accelerating Commercialization
The introduction of ShunzymeX promises to expedite the path to commercialization for clients. Stewart’s assertion highlights the technology’s capacity to create more efficient workflows, ultimately benefiting companies looking to bring their products to market more swiftly.
Synergistic Technology Integration
In addition to ShunzymeX, Fujifilm offers SymphonX™, an automated and customizable system designed to manage all downstream unit operations in one cohesive platform. Kenneth Holbourn, senior director and technical project leader, notes that the combination of these technologies further enhances the purification process, ensuring a seamless experience for developers.
Upcoming Presentation
Holbourn will present the capabilities of ShunzymeX in a session titled “Accelerating and Streamlining Microbial Process Development with a Novel Technology” on March 4, 2026, at 2:50 PM PT in Theater 5 at the Festival of Biologics. This session aims to inform attendees about the advancements in microbial process development and the advantages of adopting ShunzymeX.
Industry Implications
The introduction of ShunzymeX could significantly reshape the landscape of microbial process development. By addressing the inefficiencies of traditional methods and offering a streamlined solution, Fujifilm Biotechnologies positions itself at the forefront of innovation in the biotech sector. This technology not only enhances productivity but also aligns with the industry’s pressing need for faster and more efficient purification processes.
Key Takeaways
- ShunzymeX simplifies downstream processing for complex biologics with a novel protease.
- The technology enables efficient purification using off-the-shelf affinity resins.
-
It addresses traditional challenges in microbial downstream purification, reducing development times and improving yields.
-
ShunzymeX is compatible with various expression systems and scalable to cGMP standards.
-
The integration with SymphonX™ further enhances the purification workflow.
In conclusion, Fujifilm Biotechnologies’ ShunzymeX marks a significant advancement in microbial process development. With its ability to simplify purification and reduce timelines, this technology not only addresses existing challenges but also empowers companies to accelerate their path to commercialization. The future of biologic purification is undoubtedly brighter with innovations like ShunzymeX leading the way.
Read more → www.genengnews.com